BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29981430)

  • 1. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
    Zhang H; Han B; Lu H; Zhao Y; Chen X; Meng Q; Cao M; Cai L; Hu J
    Cancer Lett; 2018 Oct; 433():186-198. PubMed ID: 29981430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
    BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
    Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
    J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
    Kinehara Y; Nagatomo I; Koyama S; Ito D; Nojima S; Kurebayashi R; Nakanishi Y; Suga Y; Nishijima-Futami Y; Osa A; Nakatani T; Kato Y; Nishide M; Hayama Y; Higashiguchi M; Morimura O; Miyake K; Kang S; Minami T; Hirata H; Iwahori K; Takimoto T; Takamatsu H; Takeda Y; Hosen N; Hoshino S; Shintani Y; Okumura M; Kumagai T; Nishino K; Imamura F; Nakatsuka SI; Kijima T; Kida H; Kumanogoh A
    JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
    Nihira K; Miki Y; Iida S; Narumi S; Ono K; Iwabuchi E; Ise K; Mori K; Saito M; Ebina M; Sato I; Maemondo M; Yamada-Okabe H; Kondo T; Sasano H
    J Pathol; 2014 Oct; 234(2):277-88. PubMed ID: 24687913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance.
    Ray P; Raghunathan K; Ahsan A; Allam US; Shukla S; Basrur V; Veatch S; Lawrence TS; Nyati MK; Ray D
    J Biol Chem; 2020 Sep; 295(36):12661-12673. PubMed ID: 32669362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
    Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
    Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
    Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
    J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma.
    Yun X; Zhang K; Wang J; Pangeni RP; Yang L; Bonner M; Wu J; Wang J; Nardi IK; Gao M; Raz DJ
    Mol Cancer Res; 2018 Jul; 16(7):1161-1171. PubMed ID: 29720480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen Receptor β Is Involved in Acquired Resistance to EGFR-tyrosine Kinase Inhibitors in Lung Cancer.
    Sugiura H; Miki Y; Iwabuchi E; Saito R; Ono K; Sato I; Okada Y; Sasano H
    Anticancer Res; 2021 May; 41(5):2371-2381. PubMed ID: 33952462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
    Cheng C; Zhao Y; Schaafsma E; Weng YL; Amos C
    Int J Cancer; 2020 Nov; 147(9):2621-2633. PubMed ID: 32406930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
    Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
    BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
    J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
    Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
    Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
    Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
    Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.
    Matsushima S; Ohtsuka K; Ohnishi H; Fujiwara M; Nakamura H; Morii T; Kishino T; Goto H; Watanabe T
    J Thorac Oncol; 2014 Sep; 9(9):1377-84. PubMed ID: 25057940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.